The U.S. Dry Eye Syndrome Treatment Market was valued at USD 2.45 billion in 2024, and is projected to reach USD 3.47 billion by 2030, rising at a CAGR of 6.00%. Market growth in the U.S. for dry eye disease (DED) has been significantly influenced by its high prevalence. By 2024, this condition has shown notable age-related increases, particularly among women, with around 6.8% of the adult population diagnosed.
The substantial patient base has highlighted the urgent need for effective treatment options, leading to a burgeoning market for companies catering to this demographic’s needs. The aging population, particularly those aged 65 and older, has significantly contributed to the rising incidence of DED. This demographic shift has created increased demand for treatment as pharmaceutical companies and healthcare providers have adapted their strategies.
In 2023 and 2024, heightened awareness of DED, linked to increased screen time from digital devices, has further surged demand. Innovations in treatment options, including prescription medications and over-the-counter (OTC) products, have improved diagnosis rates. By 2025, new therapies such as Reproxalap, IC 265, and Acoltremon are anticipated to enhance relief and drive future market expansion.
This product will be delivered within 1-3 business days.
The substantial patient base has highlighted the urgent need for effective treatment options, leading to a burgeoning market for companies catering to this demographic’s needs. The aging population, particularly those aged 65 and older, has significantly contributed to the rising incidence of DED. This demographic shift has created increased demand for treatment as pharmaceutical companies and healthcare providers have adapted their strategies.
In 2023 and 2024, heightened awareness of DED, linked to increased screen time from digital devices, has further surged demand. Innovations in treatment options, including prescription medications and over-the-counter (OTC) products, have improved diagnosis rates. By 2025, new therapies such as Reproxalap, IC 265, and Acoltremon are anticipated to enhance relief and drive future market expansion.
U.S. Dry Eye Syndrome Treatment Market Report Highlights
- The growing prevalence of DED in approximately 20 million Americans highlights urgent treatment needs and market opportunities for companies.
- Based on type, evaporative dry eye syndrome dominated the type segment, accounting for 82.5% of the total revenue share in 2024.
- Based on drugs, Cequa is projected to grow at the fastest CAGR of 27.0% over the forecast period.
- Based on product, cyclosporine led the market in 2024, demonstrating clinical efficacy in treating dry eye syndrome, significantly increasing tear production and reducing inflammation.
- Eye drops, especially artificial tears, offer rapid relief from dry eye symptoms by lubricating the eyes and mimicking natural tears, thus dominating the dosage form segment in 2024.
- Based on prescription, OTC drugs are expected to register the fastest CAGR of 6.5% over the forecast period.
- Retail pharmacies dominated the market, with online pharmacies exhibiting the fastest CAGR of 6.6% over the forecast period.
- In August 2024, OCuSOFT launched Retaine Allergy prescription-strength antihistamine drops in the U.S., enhancing its product line focused on dry eye solutions and allergy relief.
This report addresses:
- Market intelligence to enable effective decision-making.
- Market estimates and forecasts from 2018 to 2030.
- Growth opportunities and trend analyses.
- Segment and regional revenue forecasts for market assessment.
- Competition strategy and market share analysis.
- Product innovation listings for you to stay ahead of the curve.
- COVID-19's impact and how to sustain in this fast-evolving market.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Dry Eye Syndrome Treatment Market Variables, Trends, & Scope
Chapter 4. U.S. Dry Eye Syndrome Treatment Market: Type Business Analysis
Chapter 5. U.S. Dry Eye Syndrome Treatment Market: Drugs Business Analysis
Chapter 6. U.S. Dry Eye Syndrome Treatment Market: Product Business Analysis
Chapter 7. U.S. Dry Eye Syndrome Treatment Market: Dosage Form Business Analysis
Chapter 8. U.S. Dry Eye Syndrome Treatment Market: Sales Channel Business Analysis
Chapter 9. U.S. Dry Eye Syndrome Treatment Market: Distribution Channel Business Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this U.S. Dry Eye Syndrome Treatment market report include:- Novartis AG
- AbbVie Inc.
- Sun Pharmaceutical Industries Ltd.
- Janssen Pharmaceutica (Pty.) Ltd.
- OASIS Medical, Inc.
- Viatris Inc.
- Bausch Health Companies Inc.
- Santen Pharmaceutical Co., Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.45 Billion |
| Forecasted Market Value ( USD | $ 3.47 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | United States |
| No. of Companies Mentioned | 9 |
